Author:
Horneff G.,Hospach T.,Dannecker G.,Föll D.,Haas J.P.,Girschick H.J.,Huppertz H.I.,Keitzer R.,Laws H.J.,Michels H.,Minden K.,Trauzeddel R.
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Amgen (2009) Amgen and Wyeth statement on FDA announcement about tumor necrosis factor (TNF) blockers. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2009&releaseID=1316767
2. Askling J, Fored CM, Baecklund E et al (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64:1414–1420
3. Askling J, Vollenhoven RF van, Granath F et al (2009) Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: Does the risk change with the time since start of treatment? Arthritis Rheum 60:3180–3189
4. Baecklund E, Iliadou A, Askling J et al (2006) Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 54:692–701
5. Batzler WU, Giersiepen K, Hentschel S et al (2008) Cancer in Germany 2003–2004. Incidence and trends. In: Katalinic A, Bertz J, Haberland J, Wolf U (Hrsg) 6, 1–113. 2008. Berlin, Robert-Koch-Institut, Berlin, und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. http://www.ekr.med.uni-erlangen.de/GEKID/Doc/kid2008_english.pdf
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献